Physician

Douglas M Reznick, MD

According to 2025 Medicare claims, Douglas Reznick, MD (NPI: 1124002456) practices medical oncology in the Denver-Aurora-Centennial, CO market, with the plurality of this provider's patient population coming from Arapahoe, CO. This provider's primary affiliated billing organization is ROCKY MOUNTAIN CANCER CENTERS LLP (NPI: 1518941186; TIN: 841457488) and primary practice location at 80120-4413. Reznick is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Reznick's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 502 traditional Medicare patients, billed 135,493 HCPCS/CPT codes, and received $2,548,138 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,259 prescription claims across 226 beneficiaries totaling $2,000,179 in drug costs, led by Krazati (Adagrasib). DME data shows 44 claims. Open Payments data shows 18 records totaling $8,825. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $955,195 to $2,548,138. Similarly, Part D prescription costs have moved sharply higher in recent years, from $419,192 to $2,000,179. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $1,923 to $702.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	295	78,954	$955,195
2016	526	100,791	$1,450,477
2017	556	100,694	$1,496,742
2018	561	130,970	$1,964,188
2019	607	165,535	$2,521,388
2020	563	123,892	$1,838,014
2021	525	143,766	$2,351,915
2022	573	153,091	$1,958,498
2023	511	129,295	$2,004,114
2024	502	135,493	$2,548,138

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	108	835	$419,192
2016	141	829	$449,249
2017	154	890	$544,330
2018	138	954	$579,318
2019	171	1,265	$688,394
2020	181	1,296	$915,376
2021	221	1,482	$1,415,376
2022	236	1,341	$1,338,669
2023	214	1,178	$1,692,013
2024	226	1,259	$2,000,179

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	112	$44,470
2016	N/R	128	$46,148
2017	N/R	60	$15,415
2018	N/R	84	$11,399
2019	N/R	67	$6,086
2020	N/R	113	$8,278
2021	N/R	215	$11,963
2022	N/R	198	$9,896
2023	N/R	76	$5,412
2024	N/R	44	$2,121

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	129	285	$95
96372	Injection of drug or substance under skin or into muscle	96	282	$11
80053	Blood test, comprehensive group of blood chemicals	138	545	$10
36415	Insertion of needle into vein for collection of blood sample	166	654	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	169	796	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Krazati	Adagrasib	17	510	$311,100
Tagrisso	Osimertinib Mesylate	18	540	$307,675
Mekinist	Trametinib Dimethyl Sulfoxide	18	540	$295,477
Tabrecta	Capmatinib Hydrochloride	13	364	$278,838
Eliquis	Apixaban	98	4,120	$78,095

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	18	$1,526
E1700	Jaw motion rehabilitation system	Y	N/R	11	$313
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$282

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	18	$8,825	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Douglas M. Reznick, MD?

Tedicare shows public-source Medicare data for Douglas M. Reznick, MD (NPI 1124002456), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Douglas M. Reznick, MD have ACO affiliation data?

Douglas M. Reznick, MD is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Douglas M. Reznick, MD?

Douglas M. Reznick, MD is linked to ROCKY MOUNTAIN CANCER CENTERS LLP (billing NPI 1518941186) in the available physician profile data.

Does Douglas M. Reznick, MD have Open Payments data?

Douglas M. Reznick, MD has 18 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.